Please enter the email address you used to register, then we will send you a link to choose a new password
– Oral difelikefalin did not demonstrate meaningful clinical benefit compared to placebo – Company will discontinue clinical pr...
Needham analyst Joseph Stringer reiterates Cara Therapeutics (NASDAQ:CARA) with a Buy and maintains $5 price target.
HC Wainwright & Co. analyst Oren Livnat reiterates Cara Therapeutics (NASDAQ:CARA) with a Buy and maintains $3.6 price t...
Cara Therapeutics (NASDAQ:CARA) reported quarterly losses of $(0.56) per share which missed the analyst consensus estimate of $...